COVID-19 Vaccines: Patient Choice
You have the option to receive the COVID-19 vaccine and boosters WITH or WITHOUT an office visit.
You can choose:
- Vaccine only
- Vaccine with vital sign assessment
- Vaccine with vital sign assessment and primary care office visit
As a primary care provider that strives to provide the highest level of care to patients and families, we encourage patients to engage in a primary care office visit while receiving vaccinations, including the COVID-19 vaccine. However, you have the option to choose to receive the COVID-19 vaccine only, should you wish to do so.
The cost of the actual COVID-19 vaccine distributed by the government is free. There is a standard COVID-19 vaccine administration fee which is covered by insurance plans. If you do not have insurance, there will be no cost to you for the administration of the COVID-19 vaccine.
If you choose to have a vital sign assessment and/or a primary care office visit, you will be charged for the visit which will be billed to your health insurance provider. Depending on your health insurance plan, you may be required to pay an out-of-pocket expense such as a co-pay, co-insurance, and/or a deductible.
We will never deny a health service based on inability to pay. We have a sliding-fee discount program available for eligible individuals.
We are now scheduling all members of the community ages 5 and up for COVID-19 vaccines and, when eligible, boosters. A parent or guardian must accompany patients ages 17 and under to appointments.
Vaccines for children ages 5-11
We administer kid-sized doses (10-micrograms, or one-third the amount given to teens and adults) of Pfizer’s COVID-19 vaccine for children ages 5 to 11, based on CDC recommendations. Eligible children will receive two shots, scheduled three weeks apart.
(NOTE: Children ages 5 to 11 with immune deficiencies may receive an additional primary dose of Pfizer’s vaccine as long as it is 28 days after the second shot.)
Boosters for children & teens, ages 12-17
Anyone in the age category of 12 to 17 is eligible to receive the Pfizer booster shot five months after receiving their primary two-dose series.
Booster for adults, ages 18 and older
Adults who received their Pfizer or Moderna primary vaccine at least five months ago or received a Johnson & Johnson dose at least two months ago are eligible for the booster.
Second booster for adults, ages 50 and older
Adults ages 50 and older who received an initial booster dose at least four months ago are eligible for second booster doses of the Moderna and Pfizer COVID-19 vaccines. An additional booster dose also has been recommended for individuals 12 years of age and older who are immunocompromised.
How to Schedule Your Appointment
You can make an appointment at the primary care location nearest to you by calling the location or, to avoid potential long waits due to high call volumes, by clicking on the button above and using our online appointment system.
After You Schedule Your Appointment:
You will receive a pre-visit packet via email or text message that must be completed before you arrive for your appointment.
Upon Arrival at Your Appointment:
Please bring your photo ID and insurance cards if you have them. For those who are uninsured or underinsured, we offer a sliding-fee discount program.
We offer COVID-19 testing at all of our practices. You can choose to have a COVID-19 test with or without an office visit.
*Please note: Due to a national shortage of supplies, 50-minute PCR rapid testing is limited and may not be available at the time of your appointment. If you require a PCR test and we do not have rapid PCR tests available, your test may be sent to an outside laboratory, causing a delay in your test results. Please know that 15-minute Antigen tests are readily available.
*Important Update: We are currently only receiving PCR testing supplies that test for COVID-19, Respiratory Syncytial Virus (RSV) and Influenza A and B, which is four tests in one.
Again, if you require a PCR test please know that it may need to be sent to an outside lab, and wait times will vary depending on lab processing times.
For more information on turnaround times on your PCR test, please contact:
- Health Network Laboratory (adult testing) at 1-877-402-4221
- LabCorp (children) 1-800-845-6167
*Also: COVID tests for travel plans (or other activities), are not typically covered by insurance. Patients will be billed for out-of-pocket expenses. And because of supply levels, we are sending out all PCR testing for travel and other activities to outside labs which means results can be delayed (please see above).
The Wright Center will never discriminate in our care delivery services based on ability to pay, and we have a sliding-fee discount program for eligible individuals who meet the federal poverty guidelines income requirements. We will never deny a primary or other health service based on inability to pay.
We offer self-swab tests as well as PCR and Antigen tests. Our clinicians will determine whether to use rapid-result tests based on each individual’s symptoms, exposure and risk factors.
COVID-19 Infusion Therapy
The Wright Center offers outpatient COVID-19 Infusion Therapy using Monoclonal Antibody Infusion Therapy in high-risk patients who are COVID-positive. This therapy must be administered within 10 days of COVID symptoms and/or after a positive COVID-19 diagnosis. Monoclonal Antibody infusion therapy can save lives, decrease suffering by alleviating symptoms, prevent further spread of the virus and relieve the burden on already-stressed area hospitals and ERs.
Our clinical teams have streamlined the referral process so if you test positive at one of our locations, you can be immediately scheduled for infusion therapy. We also offer this service to non-Wright Center patients within 10 days of a positive COVID-19 diagnosis. Monoclonal Antibody Infusion Therapy is easy to administer and your entire appointment and treatment will take about two hours.
To make an appointment, call:
We recommend infusion therapy patients dress warmly and even bring a blanket with them. The medicine involved requires cooler temperatures and patients often develop chills during treatment. Reading materials, personal music devices and other related entertainment are recommended to pass the time.
Update: Infusion therapy reserved for the most vulnerable
The Wright Center for Community Health has stopped using two types of COVID-19 drugs previously given to patients during monoclonal antibody infusion therapy, because federal health officials deemed the drugs are not effective against the omicron variant.
The Food and Drug Administration revoked emergency authorization on Jan. 24, 2022, for Eli Lilly’s bamlanivimab plus etesevimab and Regeneron’s casirivimab plus imdevimab. Both drugmakers had previously said the infusion drugs are less able to target omicron due to its mutations.
The Wright Center will continue to offer antibody infusion therapy to eligible patients at its primary care practices in Scranton and Jermyn, using an alternative drug that has proven more effective against omicron. However, supplies of GlaxoSmithKline’s drug, sotrovimab, are currently limited, as are existing oral antiviral drugs, paxlovid and molnupiravir. Drugmaker GlaxoSmithKline is reportedly boosting production of sotrovimab.
Until supplies of GlaxoSmithKline’s product are more widely available, The Wright Center will reserve use of antibody infusion therapy for individuals who are most vulnerable to COVID-19 and at highest risk for complications and possible hospitalization.
Antibody drugs and other treatments for coronavirus are not a substitute for vaccination. Getting vaccinated and boosted remains the best line of defense against COVID-19. The vaccines and their boosters, which are readily available to the public, have proven to be safe and effective in confronting the virus and mitigating the pandemic’s toll.
The FDA stated that the drugs made by Regeneron and Eli Lilly, which initially were effective in treating COVID-19, might be used again if they are found effective against other variants.
“In the future, if patients in certain geographic regions are likely to be infected or exposed to a variant that is susceptible to these treatments, then use of these treatments may be authorized in these regions,” according to the FDA’s statement.